Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.